Bio-Techne Announces Launch of Cultrex UltiMatrix BME to Support Organoid and Pluripotent Stem Cell Cultures
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announces the launch of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an innovative extracellular matrix hydrogel aimed at enhancing organoid and pluripotent stem cell cultures. This product features increased total protein content, optimized protein composition, and improved tensile strength, while also reducing reliance on growth factors. Dave Eansor, President of Protein Sciences Segment, emphasizes its importance for drug discovery and regenerative medicine, addressing a critical market need.
Positive
- Launch of UltiMatrix RGF BME enhances capabilities in organoid and stem cell research.
- Product improvements include increased total protein content and optimized composition.
- Reduces dependency on supplemental growth factors, potentially lowering research costs.
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -5.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, March 29, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells. UltiMatrix RGF BME addresses the market need for a dependable, high concentration cell scaffolding matrix with compositional and physical properties specifically designed for use in generating advanced 2D and 3D cell culture models. Cultrex UltiMatrix RGF BME matrix improvements include increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength while reducing the dependency on supplemental growth factors.
"Cultrex UltiMatrix BME offers improvements to matrix hydrogels that are urgently needed to support the increased use of organoids and pluripotent stem cells for drug discovery research, personalized medicine, and regenerative medicine. We're very excited to add this advanced matrix to our portfolio," said Dave Eansor, President, Protein Sciences Segment.
The full line of Cultrex BME can be found on the R&D Systems Website: Cultrex BME
Bio-Techne continues to support organoid and stem cell research by manufacturing reagents critical for cell culture, including recombinant proteins, small molecules, extracellular matrices, media and media supplements.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
David Clair, Senior Director, Investor Relations and Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-launch-of-cultrex-ultimatrix-bme-to-support-organoid-and-pluripotent-stem-cell-cultures-301254828.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.